Researcher Database | Faculty of Pharmaceutical Sciences Department of Pharmacy | Maiko Machida |

（Last updated : 2025-03-25 17:38:03）

Visruth.jpg not found

Maiko Machida

Department / Course Hokkaido University of Science Faculty of Pharmaceutical Sciences Department of Pharmacy

Job Professor

Academic background
2007/08 Degree Acquisition
1998/03 Degree Acquisition

Present specialized field
Others, Others

Book and thesis
Papers	Clinical research on withdrawal symptoms of dexmedetomidine in neonates.,pp.33-37 (Co-authored) 2024/04/30
Papers	Integrated predictors by propensity scoring with tumor markers and plasma levels of microRNA-21-5p, IL-17, and IL-10 complement early detection of hepatocellular carcinoma in patients with liver cirrhosis. Technology in Cancer Research & Treatment 20,pp.1-15 (Co-authored) 2023/11/13
Papers	A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer Journal of Pharmaceutical Health Care and Sciences 8 (29) (Co-authored) 2022/10/11
Papers	The Concentration of 8-Hydroxy-2′-Deoxyguanosine in Plasma During the Menstrual Cycle in Young Japanese Women Women's health reports 3 (1),pp.267-273 (Co-authored) 2022/03/01
Papers	Methotrexate mediates the integrity of intestinal stem cells partly through nitric oxide-dependent Wnt/β-catenin signaling in methotrexate-induced rat ileal mucositis Journal of Pharmacological Sciences 148 (3),pp.281-285 (Co-authored) 2022/01
Display All（16）

Academic conference presentation
2025/03/27	Effects of tetracycline antibiotics in an inflammation model using RAW264.7 cells
2025/03/27	The involvement of miRNAs in the changes of platelet/lymphocyte ratio due to pembrolizumab treatment differs between non-small cell lung cancer tumors.
2025/03/27	The involvement of miRNAs in the changes of the Systemic immune-inflammation index due to pembrolizumab treatment differs between non-small cell lung cancer tumors.
2025/03/27	Regulatory factors of the neutrophil/lymphocyte ratio during pembrolizumab treatment differ between non-small cell lung cancer types.
2025/03/27	Search for gastrointestinal drugs effective in preventing the onset of everolimus-induced interstitial lung disease using a drug adverse reaction database and in vitro methods
Display All（28）